Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05357690 · ClinicalTrials.gov registry record · Phase 2
A Study of Stellate Ganglion Block for Prevention of Atrial Fibrillation
A Phase 2 study of Atrial Fibrillation, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
- 1
- Study location
NCT05357690: Recruiting Phase 2 study of Atrial Fibrillation, sponsored by Mayo Clinic.
NCT05357690 is a Phase 2 study of Atrial Fibrillation that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 220 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05357690, a Phase 2 study of Atrial Fibrillation, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test if a nerve block procedure called a stellate ganglion block can help decrease the chance of atrial fibrillation after surgery. Atrial fibrillation is the abnormal, fast beating of the upper chambers of the heart. Stellate ganglion blockade has shown to decrease other types of abnormal heart rhythms as well as decrease the chance of atrial fibrillation.
Primary Outcome
Percentage of subjects to experience postoperative atrial fibrillation (POAF)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Bupivacaine
- PROCEDURE Stellate ganglion block
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2023-04-19 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What NCT05357690 shows while recruiting
NCT05357690 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05357690 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05357690 about?
NCT05357690 is a clinical study titled "A Study of Stellate Ganglion Block for Prevention of Atrial Fibrillation". The purpose of this study is to test if a nerve block procedure called a stellate ganglion block can help decrease the chance of atrial fibrillation after surgery. Atrial fibrillation is the abnormal, fast beating of the upper chambers of the heart. Stellate ganglion blockade has shown to decrease o...
What is the current status of trial NCT05357690?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2023-04-19. Estimated completion is 2026-12.
What conditions does trial NCT05357690 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT05357690?
The interventions under investigation include: Placebo (DRUG), Bupivacaine (DRUG), Stellate ganglion block (PROCEDURE).
Who is sponsoring clinical trial NCT05357690?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05357690 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05357690's enrollment target sits among peer trials
220 98th of 202 higher than 104 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
RECRUITING · Phase 2
-
Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study
RECRUITING · Phase 2
-
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
RECRUITING · Phase 2
-
ECG Validation Study
ACTIVE NOT RECRUITING · Phase 2
-
A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI